PreveCeutical Announces Rescheduled Date for Annual General and Special Meeting
PreveCeutical Medical (OTCQB: PRVCF) has rescheduled its annual general and special meeting from August 15 to September 5, 2025. At the meeting, shareholders will vote on key matters including director elections and the appointment of Davidson & Company LLP as auditors.
A significant proposal involves the distribution of up to 12 million common shares of BioGene Therapeutics to PreveCeutical shareholders through a plan of arrangement. This strategic move will result in shareholders owning stakes in both companies: BioGene, focusing on Dual Gene Therapy development, and PreveCeutical, continuing its work on preventive and curative therapies using organic products.
PreveCeutical Medical (OTCQB: PRVCF) ha posticipato la sua assemblea generale annuale e straordinaria dal 15 agosto al 5 settembre 2025. Durante l'incontro, gli azionisti voteranno su questioni fondamentali, tra cui l'elezione dei direttori e la nomina di Davidson & Company LLP come revisori dei conti.
Una proposta importante riguarda la distribuzione fino a 12 milioni di azioni ordinarie di BioGene Therapeutics agli azionisti di PreveCeutical tramite un piano di riorganizzazione. Questa mossa strategica permetter脿 agli azionisti di detenere partecipazioni in entrambe le societ脿: BioGene, specializzata nello sviluppo di terapie geniche duali, e PreveCeutical, che prosegue il suo lavoro su terapie preventive e curative basate su prodotti organici.
PreveCeutical Medical (OTCQB: PRVCF) ha reprogramado su junta general anual y extraordinaria del 15 de agosto al 5 de septiembre de 2025. En la reuni贸n, los accionistas votar谩n sobre asuntos clave, incluyendo la elecci贸n de directores y el nombramiento de Davidson & Company LLP como auditores.
Una propuesta significativa implica la distribuci贸n de hasta 12 millones de acciones ordinarias de BioGene Therapeutics a los accionistas de PreveCeutical mediante un plan de reorganizaci贸n. Este movimiento estrat茅gico permitir谩 que los accionistas posean participaciones en ambas compa帽铆as: BioGene, centrada en el desarrollo de terapia g茅nica dual, y PreveCeutical, que contin煤a su trabajo en terapias preventivas y curativas basadas en productos org谩nicos.
PreveCeutical Medical (OTCQB: PRVCF)電� 鞐半 鞚茧皹 氚� 韸闺硠 欤检＜齑濏殞毳� 8鞗� 15鞚检棎靹� 2025雲� 9鞗� 5鞚�搿� 鞐瓣赴頄堨姷雼堧嫟. 須岇潣鞐愳劀 欤检＜霌れ潃 鞚挫偓 靹犾稖瓿� Davidson & Company LLP鞚� 臧愳偓鞚� 鞛勲獏 霌� 欤检殧 鞎堦贝鞐� 雽�頃� 韴憸頃� 鞓堨爼鞛呺媹雼�.
欷戩殧頃� 鞝滌晥 欷� 頃橂倶電� BioGene Therapeutics鞚� 氤错喌欤� 斓滊寑 1,200毵� 欤�毳� PreveCeutical 欤检＜霌れ棎瓴� 氚半秳頃橂姅 瓿勴殟鞛呺媹雼�. 鞚� 鞝勲灥鞝� 臁办箻電� 欤检＜霌れ澊 霊� 須岇偓鞐� 氇憪 歆�攵勳潉 氤挫湢頃橁矊 頃橂┌, BioGene鞚� 鞚挫 鞙犾爠鞛� 旃橂 臧滊皽鞐� 歆戩頃橁碃 PreveCeutical鞚� 鞙犼赴雴� 鞝滍拡鞚� 頇滌毄頃� 鞓堧癌 氚� 旃橂鞖� 旃橂鞝滊ゼ 瓿勳啀 臧滊皽頃� 瓴冹瀰雼堧嫟.
PreveCeutical Medical (OTCQB : PRVCF) a report茅 son assembl茅e g茅n茅rale annuelle et extraordinaire du 15 ao没t au 5 septembre 2025. Lors de cette r茅union, les actionnaires voteront sur des points cl茅s, notamment l'茅lection des administrateurs et la nomination de Davidson & Company LLP en tant qu鈥檃uditeurs.
Une proposition importante concerne la distribution pouvant aller jusqu'脿 12 millions d鈥檃ctions ordinaires de BioGene Therapeutics aux actionnaires de PreveCeutical via un plan d鈥檃rrangement. Cette d茅marche strat茅gique permettra aux actionnaires de d茅tenir des participations dans les deux soci茅t茅s : BioGene, sp茅cialis茅e dans le d茅veloppement de th茅rapies g茅niques doubles, et PreveCeutical, qui poursuit ses travaux sur des th茅rapies pr茅ventives et curatives utilisant des produits biologiques.
PreveCeutical Medical (OTCQB: PRVCF) hat seine j盲hrliche Haupt- und Sonderversammlung vom 15. August auf den 5. September 2025 verschoben. Bei der Versammlung werden die Aktion盲re 眉ber wichtige Angelegenheiten abstimmen, darunter die Wahl der Direktoren und die Ernennung von Davidson & Company LLP als Wirtschaftspr眉fer.
Ein bedeutender Vorschlag umfasst die Verteilung von bis zu 12 Millionen Stammaktien von BioGene Therapeutics an die PreveCeutical-Aktion盲re im Rahmen eines Umstrukturierungsplans. Dieser strategische Schritt erm枚glicht es den Aktion盲ren, Anteile an beiden Unternehmen zu halten: BioGene, das sich auf die Entwicklung der Dual-Gentherapie konzentriert, und PreveCeutical, das seine Arbeit an pr盲ventiven und kurativen Therapien mit organischen Produkten fortsetzt.
- Strategic separation will allow both companies to access targeted capital more effectively
- Shareholders will receive shares in two distinct companies, potentially increasing value
- Focused business models may improve operational efficiency for both entities
- Corporate restructuring may create additional administrative costs
- Potential dilution of management focus across two separate entities
Vancouver, British Columbia--(Newsfile Corp. - July 9, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, further to its News Release of June 25, 2025, it has rescheduled its annual general and special meeting from August 15, 2025 to September 5, 2025 at which the shareholders (the "PreveCeutical Shareholders") of the Company will be asked to approve:
the election of Stephen Van Deventer, Makarand Jawadekar, Linnéa Olofsson, Kathleen Rokita and C. Evan Ballantyne as directors of the Company;
the ratification of the appointment of Davidson & Company LLP, Chartered Professional Accountants, as the auditors of PreveCeutical for the financial year ending December 31, 2024 and 2025;
a plan of arrangement under the provisions of Division 5 of Part 9 of the Business Corporations Act (British Columbia), pursuant to which the Company will distribute up to 12,000,000 common shares of BioGene Therapeutics Inc. ("BioGene") to the PreveCeutical Shareholders; (the "Arrangement and Distribution") and
the adoption of the PreveCeutical's Omnibus Equity Incentive Plan.
Once the Arrangement and Distribution is complete, the PreveCeutical Shareholders will own shares in two companies: BioGene, which will focus on the development of the Dual Gene Therapy program, and PreveCeutical, which will continue to focus on developing innovative options for preventive and curative therapies utilizing organic and nature identical products.
PreveCeutical believes that the Arrangement and Distribution is in the best interests of PreveCeutical and the PreveCeutical Shareholders for numerous reasons, including that separating PreveCeutical and BioGene will expand both PreveCeutical's and BioGene's potential shareholder base and access to capital for research, development and clinical trials by allowing investors that want specific ownership in the particular business of BioGene the opportunity to invest directly in BioGene rather than through PreveCeutical.
About PreveCeutical
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit follow us on Twitter: and Facebook:
On behalf of the Board of Directors of PreveCeutical
Stephen Van Deventer, Chairman and Chief Executive Officer
For further information, please contact:
Stephen Van Deventer: +1 604 306 9669
Or Investor Relations
[email protected]
Neither the CSE nor any Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit
FAQ
When is PreveCeutical's (PRVCF) rescheduled annual general meeting in 2025?
How many BioGene Therapeutics shares will PRVCF shareholders receive in the distribution?
What will be the focus of BioGene Therapeutics after the separation from PRVCF?
What will PreveCeutical Medical focus on after the BioGene separation?
Who are the proposed directors for PreveCeutical's board?
